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Introduction

Conclusion

Recently Temozolomide (TMZ) has become the more commonly
used analog of DTIC-related oral agents. Although the response
rates achieved by TMZ alone are less than satisfactory, there is great
interest in identifying compounds that could be used in combination
therapy. We have previously demonstrated that the bioflavonoid
quercetin (Qct) promotes a p53-mediated response in melanoma and
sensitizes melanoma to DTIC. Here we demonstrate that Qct also
sensitizes cells to TMZ by a mechanism that involves the modulation
of a truncated p53 family member, ΔNp73.

This study demonstrates that Qct can sensitize cells to TMZ and
that the mechanisms of sensitization involve modulation of p53
family members. These results strongly suggest combination with
hyperthermia in this treatment scheme. The inhibition of heatinduced p53/HSF1 by inhibiting p53 would diminish HSP70 levels
thereby enhancing the heat sensitization of DNA-damage induced
cell death [Sharma A, et al. Cancer Sci. 2010 Jan 28. Epub ahead of print].

Methods
DB-1 (p53 wild type), and SK Mel 28 (p53 mutant) human melanoma
cell lines were treated with TMZ (400 μM) for 48 hr followed by
exposure to Qct (75 μM) for 24 hr. Cell death was determined by
Annexin V-FITC staining, and immunocytochemical analysis was
carried out to determine protein translocation.

Results
After treatment with TMZ, DB-1 cells demonstrated increased
phosphorylation of mutated ATM and p53. However, the cells were
resistant to TMZ-induced apoptosis and the resistance was associated
with an increase in nuclear localization of ΔNp73. Qct treatment
in combination with TMZ abolished drug insensitivity and caused
a more than additive induction of apoptosis compared to either
treatment alone. Treatment with Qct caused redistribution of ΔNp73
into both the cytoplasm and nucleus, which has been associated
with increased p53 transcriptional activity. Knockdown of ΔNp73
restored PARP cleavage in the TMZ treated cells, confirming its antiapoptotic role. The response to treatment was predominantly p53
mediated, as the p53 mutant SK Mel 28 cells did not show significant
enhancement of apoptosis.

4

BODINEJOURNAL

Supported in part by NIH P01 CA36690 and K22 DE 16096.

